TFPI Antibody [Alexa Fluor® 405]

• Reactivity: Hu
• Applications: WB, IP
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Alexa Fluor 405

TFPI Antibody [Alexa Fluor® 405] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human TFPI
  Asp29-Lys282
  Accession # P10646
• Specificity: Detects human TFPI in direct ELISAs and Western blots. In directs ELISAs, less than 10% cross‑reactivity with recombinant mouse (rm) TFPI is observed and less than 1% cross-reactivity with recombinant human TFPI-2, and rmTFPI-2 is observed.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Immunoprecipitation
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for TFPI Antibody [Alexa Fluor® 405]

• convertin
• EPI
• EPITFPI1LACITFI
• Extrinsic pathway inhibitor
• LACI
• Lipoprotein-associated coagulation inhibitor
• TFPI
• tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor)
• tissue factor pathway inhibitor

Background

Human TFPI, also known as lipoprotein-associated coagulation inhibitor (LACI) and extrinsic pathway inhibitor (EPI), is a physiological inhibitor of extrinsic pathway of coagulation and has biological functions of anticoagulation and anti-inflammation (1). It is a secreted protein with a N-terminal acidic region, three Kunitz (K) domains separated with by two linker regions, and a C-terminal basic region (2). The first K domain (residues 54 to 104) inhibits coagulation factor VIIa complexed to tissue factor (TF). The second K domain (residues 125 to 175) inhibits factor Xa. The third K domain (residues 217 to 267) binds to heparin (3). The C-terminal basic region may have several functions. For example, it plays an important role in binding of TFPI to cell surfaces (2). The purified rhTFPI ends at residue 282 and does not contain the last 20 residues (residues 283 to 302) in the C-terminal region. It inhibits the activity of Recombinant Human Coagulation Factor VII (Catalog # 2338-SE) in the presence of Recombinant Human Coagulation Factor III/Tissue Factor (Catalog # 2339-PA).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.